ArticleClinical and experimental immunology2006
Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.
Article in Clinical and experimental immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities.Current treatment options in oncology · 2023Review
- Review
- Dendritic Cell Vaccines in Ovarian Cancer.Frontiers in immunology · 2020Review
- Dendritic cell-based cancer immunotherapy for colorectal cancer.World journal of gastroenterology · 2016Review
- A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?Facts, views & vision in ObGyn · 2015Article
- Interleukin 12: still a promising candidate for tumor immunotherapy?Cancer immunology, immunotherapy : CII · 2014Review
- A potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy.PloS one · 2014Article
- Trial watch: Dendritic cell-based interventions for cancer therapy.Oncoimmunology · 2012Article
- Cancer immunotherapy and nanomedicine.Pharmaceutical research · 2011Review
- An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine.Cancer immunology, immunotherapy : CII · 2011Article
- Current immunotherapeutic approaches in pancreatic cancer.Clinical & developmental immunology · 2011Review
- Ovarian cancer immunotherapy: opportunities, progresses and challenges.Journal of hematology & oncology · 2010Review
- Regulation of tumor immunity by tumor/dendritic cell fusions.Clinical & developmental immunology · 2010Review
- Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.Journal of biomedicine & biotechnology · 2010Article
- Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Cancer vaccine by fusions of dendritic and cancer cells.Clinical & developmental immunology · 2009Review
- In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells.Journal of translational medicine · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cell (DC) vaccines might induce both anti-tumour immunity and autoimmunity. In this report, we demonstrate elevated levels of anti-nuclear antibody (ANA) in the sera of patients with cancer who had received immunotherapy with a dendritic/tumour-fusion vaccine. Twenty-two patients were treated with DC vaccine of fusion cells composed of autologous DCs and tumour cells (DC/tumour-fusion vaccine), which was generated by treating each cell type with polyethylene glycol. Nine of the 22 patients were treated with both the DC/tumour-fusion vaccine and systemic administration of recombinant human interleukin (rhIL)-12. Serum levels of ANA were examined with an enzyme-linked immunosorbent assay kit. One patient with gastric carcinoma (patient 1, DC/tumour-fusion vaccine alone), one patient with breast cancer (patient 2, DC/tumour-fusion vaccine alone) and one patient with ovarian cancer (patient 3, DC/tumour-fusion vaccine + rhIL-12) showed significant elevations of serum ANA levels during treatment. In patient 1 malignant ascitic effusion resolved and serum levels of tumour markers decreased. Patients 2 and 3 remained in good physical condition during treatment for 24 and 9 months, respectively. Immunoblot analysis indicated antibody responses to autologous tumour cells after vaccination in patient 2. None of the treated patients showed clinical symptoms suggesting autoimmune disease. Patients with elevated serum levels of ANA had significantly longer treatment periods than those without it. Elevated serum levels of ANA after DC/tumour-fusion cell vaccine might be associated with anti-tumour immune response induced by the vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.